Shire plc was a global biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other specialty conditions. Headquartered in the United Kingdom, the company specialized in areas such as hematology, immunology, neuroscience, and genetic diseases.
Shire was acquired by Takeda Pharmaceutical Company in 2019 and is no longer an independent entity. Its portfolio and operations have been integrated into Takeda’s rare disease and specialty care businesses.
Also known as Shire Pharmaceuticals.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
